Executive record
Alpha ID: alpha:person:david-hallettVersion: public-0As of: 2026-10-05
Leadership, in context.
Connect capital, control, accountability, and evidence.
Explore the record
ResponsibilitiesInspect board appointments and committee mandates.ExperienceReview career history and qualifications in context.Economic interestsExamine disclosed incentives and ownership.Key Claims
- Executive titleExecutive title: Chief Scientific OfficerRXRX DEF 14A executive officers
- AI and ML experienceAI and machine learning experience reported in filingsRXRX DEF 14A executive officers
- Cybersecurity experienceCybersecurity experience: not identified in the cited filingRXRX DEF 14A executive officers
- Executive companyExecutive at RECURSION PHARMACEUTICALS, INC.RXRX DEF 14A executive officers
Biography
Dr. David Hallett has served as Chief Scientific Officer since November 2024, joining Recursion following the business combination with Exscientia where he held roles including COO, CSO, and Interim CEO. In 2026, he was named an AI Champion for the life sciences sector by the UK Government, helping to guide a national vision for AI adoption.
Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.
Board service
Board service coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageExecutive career
- 2026 to end not publishedExecutive title: Chief Scientific Officer · Organization not publishedRXRX DEF 14A executive officers
Claims
Compensation
Compensation coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageConflicts and accountability
Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.
Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.
Evidence, history and coverage
Additional published Claims
Published evidence records
1 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.
RXRX DEF 14A executive officers
sec filing · Source published: Apr 30, 2026 · Retrieved: May 5, 2026
Supports 5 claims
- AI and ML experience: AI and machine learning experience reported in filings · Claim reviewed: May 5, 2026
- Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 5, 2026
- Executive company: Executive at RECURSION PHARMACEUTICALS, INC. · Claim reviewed: May 5, 2026
- Executive title: Executive title: Chief Scientific Officer · Claim reviewed: May 5, 2026
- Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 5, 2026
No published record changes are available in this projection.
Identity
unclaimed
Evidence
source reported
Evaluation
Unknown
Monitoring
Unknown
Authority
Unknown
Freshness
Observed 2026-10-05
- Biography
- published
- Board service
- not observed
- Executive career
- published
- Education and qualifications
- not observed
- Compensation
- not observed
- Conflicts and accountability
- not observed
- Background screening
- out of scope